Recently developed helper virus-free methods of herpes simplex virus (HSV) amplicon vector packaging provide stocks that are virtually devoid of the cytotoxic component normally associated with traditional helper virus-based packaging methods. These approaches involve cotransfection of amplicon plasmid DNA with either a five-cosmid set or a bacterial artificial chromosome (BAC) that contains the HSV genome without its cognate pac signals. Helper virus-free amplicon packaging produces low-titer stocks (Ͻ10 5 expressing particles/ml) that exhibit a high frequency of pseudotransduction. In an effort to enhance amplicon titers, we introduced in trans a genomic copy of the virion host shutoff (vhs) protein-encoding gene UL41 into both cosmid-
Introduction
The herpes simplex virus (HSV)-derived amplicon vector is an attractive gene delivery tool for the central nervous system due to its ease of manipulation, large transgene capacity, and natural neurotropism. [1] [2] [3] [4] [5] Efforts to bring this vector system into the clinical arena for treating neurodegenerative diseases have been hampered by potential cytotoxicities that are associated with traditional methods of virus packaging. This problem mainly involves the copackaging of helper virus that encodes cytotoxic and immunogenic viral proteins. Newer methods of packaging have been developed that result in 'helper virus-free' amplicon stocks. 6, 7 Stocks produced by these means, however, are typically of low titer (Ͻ10 5 expression units/ml), allowing for modest scale in vitro experimentation. Such low titers discourage investigators from performing the large animal studies required to develop and assess potential amplicon-directed therapies in humans.
Not only do early generation helper virus-free packaging strategies lead to lower amplicon titers than traditional methods, they also produce stocks that exhibit a high frequency of pseudotransduction events when used to infect a variety of cell types. Viral stock-derived gene product appears as punctate material localized to cellular and BAC-based packaging strategies. Cotransfection of this plasmid with the amplicon and packaging reagents results in a 10-fold higher amplicon titer, and stocks that do not exhibit the pseudotransduction phenomenon. To further enhance packaging efficiency, the HSV transcriptional activator VP16 was introduced into packaging cells 1 day before the packaging components. Pre-loading of packaging cells with VP16 led to an additional enhancement of amplicon titers, an effect that did not occur in the absence of vhs. Increased helper virus-free amplicon titers resulting from these modifications will make in vivo transduction experiments more feasible. Gene Therapy (2001) 8, 111-120.
vesicles, instead of throughout the cell as is observed following vector-directed de novo expression. This phenomenon is either a consequence of vector transgene product from packaging cells that co-purifies with the virus or is the product of inefficient amplicon packaging. Pseudotransduction is not readily observed with stocks derived from helper virus-based strategies, suggesting that optimal packaging conditions do not yet exist for helper virus-free strategies.
Optimal propagation of wild-type HSV virions requires orderly progression of ␣, ␤, and ␥ gene transcription following infection of a host cell. This is achieved by delivery of copackaged proteins carried by the virion that facilitate co-opting of cellular transcription machinery and transactivation of viral ␣ gene promoters. Therein lie the fundamental differences that exist between helper virus-free packaging and traditional helper virus-based packaging methods. Helper virusbased packaging involves superinfection of an amplicon DNA-transfected monolayer of packaging cells with a replication-defective helper virus. The helper virus genome, as in the case of wild-type HSV, is delivered to the cell in a complex with copackaged proteins, including VP16 and virion host shutoff (vhs). The HSV vhs protein functions to inhibit the expression of genes in infected cells via destabilization of both viral and host mRNAs. Because vhs plays such a vital role in establishment of the HSV replicative cycle and as a potential structural protein, its presence early during amplicon packaging may account for the higher titers observed for helper virus-based packaging. VP16 is another important copackaged protein that resides in the helper virus nucleocapsid and is responsible for activating transcription of HSV immediate-early genes to initiate the cascade of lytic cycle-related viral protein expression.
Helper virus-free methods of amplicon packaging, conversely, involve cotransfection of naked DNA forms of either a HSV genome-encoding cosmid set or BAC reagent with an amplicon vector. In this instance, the HSV genome gains access to the cell without copackaged vhs or VP16. The initiation and temporal progression of HSV gene expression is potentially not optimal for production of packaged amplicon vectors due to the absence of these important HSV proteins.
Because helper virus-free packaging reagents are delivered to a host cell without important viral regulatory proteins, the efficiency of amplicon packaging may likely be increased by introduction of vhs and VP16 during the initial phase of virus propagation. To this end, a vhsencoding DNA segment was included in the packaging protocol as a cotransfection reagent. Additionally, packaging cells were 'pre-loaded' with VP16 to mimic its presence during helper virus-mediated amplicon packaging. These modifications in aggregate led to a 30-to 50-fold enhancement of packaged amplicon vector titers, nearly approximating titers obtained using helper virus-based traditional approaches. The resultant viral stocks also did not exhibit the pseudotransduction phenomenon. Improvements such as these to helper virus-free techniques of HSV amplicon vector production increase the likelihood that large-scale in vivo applications of amplicon vectors will be attainable.
Results
The full potential of HSV amplicon vectors for therapeutic gene delivery has not been realized. Widespread use of this vector system has been hampered by helper virus-mediated cytotoxicity associated with traditionally packaged amplicon stocks or by the low titers obtained from helper virus-free production methods. Helper virusfree methods of packaging hold the most promise as resultant stocks exhibit little or no cytotoxicity. Modifications to such packaging strategies could be made to increase viral titers.
Our laboratory has utilized both cosmid-and BACbased methods of helper virus-free packaging previously described. [6] [7] [8] The low titers observed for helper virus-free methods may be a result of the sub-optimal state of the HSV genome at the beginning of amplicon production, as the genome is without copackaged viral regulators vhs and VP16. To determine if introduction of vhs into the packaging scheme could increase amplicon titers and quality, we cloned a genomic segment of the UL41 gene into pBluescript and added this plasmid (pBSKS(vhs)) to the cotransfection protocols to provide vhs in trans. The genomic copy of UL41 contained the transcriptional regulatory region and flanking cis elements believed to confer native UL41 gene expression during packaging. When pBSKS(vhs) was added to the packaging protocols for production of a ␤-galactosidase (lacZ)-expressing amplicon (HSVlac), a maximum of 10-fold enhanced amplicon expression titers was observed for both cosmidand BAC-based strategies (Figure 1a and b, respectively). As observed previously, the expression titers for HSVlac virus produced by the BAC-based method were approxi- mately 500-to 1000-fold higher than stocks produced using the modified cosmid set. Even though titers were disparate between the differently prepared stocks, the effect of additionally expressed vhs on amplicon titers was analogous.
The punctate appearance of reporter gene product (pseudotransduction), a phenomenon associated with first-generation helper virus-free stocks, was substantially diminished in vitro when vhs was included in BACbased packaging of a ␤-galactosidase-expressing (HSVlac; Figure 2a Gene Therapy mice. Four days following infection, animals were killed and analyzed for GFP-positive cells present in the striatum (Figure 2e and f). The numbers of cells transduced by HSVPrPUC/CMVegfp prepared in the presence of vhs were significantly higher than in animals injected with stocks produced in the absence of vhs ( Figure 2g ). In fact, it was difficult to identify GFP-positive cells definitively in animals transduced with vhs(−) amplicon stocks.
The mechanism by which vhs expression resulted in higher apparent amplicon titers in helper virus-free packaging could be attributed to one or several properties of vhs. The UL41 gene product is a component of the viral tegument and could be implicated in structural integrity, and its absence could account for the appearance of punctate gene product material following transduction. For example, the viral particles may be unstable as a consequence of lacking vhs. Thus, physical conditions, such as repeated freeze-thaw cycles or long-term storage, may have led to inactivation or destruction of vhs-lacking virions at a faster rate than those containing vhs.
The stability of HSVPrPUC/CMVegfp packaged via the BAC method in the presence or absence of vhs was analyzed initially with a series of incubations at typically used experimental temperatures. Viral aliquots from prepared stocks of HSVPrPUC/CMVegfp were incubated at 4, 22 or 37°C for periods up to 3 h. Virus recovered at time points 0, 30, 60, 120 and 180 min were analyzed for their respective expression titer on NIH 3T3 cells. The rates of decline in viable amplicon particles, as judged by their ability to infect and express GFP, did not differ significantly between the vhs(+) and vhs(−) stocks (Figure 3a-c). Another condition that packaged amplicons encounter during experimental manipulation is freezethaw cycling. Repetitive freezing and thawing of virus stocks is known to diminish numbers of viable particles, and potentially the absence of vhs in the tegument of BAC-packaged amplicons leads to sensitivity to freeze fracture. To test this possibility, viral aliquots were exposed to a series of four freeze-thaw cycles. Following each cycle, samples were removed and titered for GFP expression on NIH 3T3 cells as described previously. At the conclusion of the fourth freeze-thaw cycle, the vhs(−) HSVPrPUC/CMVegfp stock exhibited a 10-fold diminution in expression titers as opposed to only a two-fold decrease for vhs(+) stocks (Figure 3d ). This observation suggests that not only do vhs(+) stocks have increased expression titers, but the virions are more stable when exposed to temperature extremes, as determined by repetitive freeze-thaw cycling.
The native HSV genome enters the host cell with several viral proteins besides vhs, including the strong transcriptional activator VP16. Once within the cell, VP16 interacts with cellular transcription factors and HSV genome to initiate immediate-early gene transcription. Under helper virus-free conditions, transcriptional initiation of immediate-early gene expression from the HSV genome may not occur optimally, thus leading to lower than expected titers. To address this issue, a VP16 expression construct was introduced into packaging cells before cosmid/BAC, amplicon, and pBSKS(vhs) DNAs, and resultant amplicon titers were measured. To achieve regulated expression a glucocorticoid-controlled VP16 expression vector was used (pGRE 5 vp16).
The pGRE 5 vp16 vector was introduced into the pack-
Figure 3 Presence of vhs during amplicon packaging imparts freeze/fracture stability, but does not enhance thermostability. BAC-packaged HSVPrPUC/CMVegfp stocks produced in the presence (circles) or absence (squares) of vhs were incubated at 0°C (a), 22°C (b), or 37°C (c) for varying time periods. At 0, 30, 60, 120 and 180 min following initiation of the incubations, aliquots were removed, titered on NIH 3T3 cells, and expression titer data represented as green-forming units per milliliter. Another set of HSVPrPUC/CMVegfp stocks were subjected to a series of freeze-thaw cycles to determine sensitivity of viral particles to freeze fracture. Following each cycle, aliquots were removed, titered on NIH 3T3 cells, and expression titer data represented as green-forming units per milliliter (gfu; d). The asterisk indicates a statistically significant difference (RMANOVA, P Ͻ 0.001) between amplicon stocks packaged with BAC alone and those packaged with BAC in the presence of pBS(vhs).
aging cells 24 h before transfection of the regular packaging DNAs. HSVlac was packaged in the presence or absence of vhs and/or VP16 and resultant amplicon stocks were assessed for expression titer. Some packaging cultures received 100 nm dexamethasone at the time of pGRE 5 vp16 transfection to induce VP16 expression strongly; others received no dexamethasone. Introduction of pGRE 5 vp16 in an uninduced (basal levels) or induced state (100 nm dexamethasone) had no effect on HSVlac titers when vhs was absent from the cosmid-or BACbased protocol (Figure 4a and b) . In the presence of vhs, addition of pGRE 5 vp16 led to either a two-or five-fold enhancement of expression titers over those of stocks packaged with only vhs (cosmid-and BAC-derived stocks, respectively; Figure 4a and b). The effect of 'uninduced' pGRE 5 vp16 on expression titers suggested that VP16 expression was occurring in the absence of dexamethasone. To examine this, Western blot analysis with a VP16-specific monoclonal antibody was performed using lysates prepared from BHK cells transfected with the various packaging components. Cultures transfected with pGRE 5 vp16/BAC/pBSKS(vhs) in the absence of dexamethasone did show VP16 levels intermediate to cultures transfected either with BAC alone (lowest) or those transfected with pGRE 5 vp16/BAC/pBSKS(vhs) in the presence of 100 nm dexamethasone (highest) ( Figure  4c ). There was no difference in level of pGRE 5 vp16-mediated expression in the presence or absence of BAC, nor did dexamethasone treatment induce VP16 expression from the BAC (data not shown). VP16-mediated enhancement of packaged amplicon expression titers could be due to increased DNA replication and packaging of amplicon genomes. Conversely, the additional VP16 that is expressed via pGRE 5 vp16 could be incorporated into virions and act by increasing vector-directed expression in transduced cells. To test the possibility that VP16 is acting by increasing replication in the packaging cells, concentrations of vector genomes in BAC-derived vector stocks were determined. HSVlac stocks produced in the presence or absence of vhs and/or VP16 were analyzed using a 'real-time' quantitative PCR method. The concentration of vector genome was increased two-fold in stocks prepared in the presence of VP16 and this increase was unaffected by the presence of vhs ( Figure 5 ).
There is a possibility that addition of viral proteins, like vhs and VP16, to the packaging process may lead to vector stocks that are inherently more cytotoxic. The amplicon stocks described above were examined for cytotoxicity using a lactate dehydrogenase (LDH) releasebased cell viability assay. Packaged amplicon stocks were used to transduce NIH 3T3 cells and 48 h following infection, viability of the cell monolayers was assessed by the LDH-release assay. Amplicon stocks produced in the presence of vhs and VP16 displayed less cytotoxicity on a per virion basis than stocks packaged using the previously published BAC-based protocol ( Figure 6 ). 7 
Discussion
Wild-type HSV virions contain multiple regulatory proteins that prepare an infected host cell for virus propagation. These virally encoded regulators, which are localized to the tegument and nucleocapsid, include vhs and VP16, respectively. The UL41 gene-encoded vhs protein exhibits an essential endoribonucleolytic cleavage activity during lytic growth that destabilizes both cellular and viral mRNA species. 9 Vhs-mediated ribonucleolytic activity appears to prefer the 5Ј ends of mRNAs over 3Ј termini, and the activity is specific for mRNA, as vhs does not act upon ribosomal RNAs. 10 Vhs also serves a structural role in virus particle maturation as a component of the tegument. HSV isolates that possess disrup- tions in UL41 demonstrate abnormal regulation of IE gene transcription and significantly lower titers than wild-type HSV-1, 11 presumably due to the absence of vhs activity. Therefore, because vhs is essential for efficient production of viable wild-type HSV particles, it likely plays a similarly important role in packaging of HSV-1-derived amplicon vectors.
The term 'pseudotransduction' refers to virion expression-independent transfer of biologically active
Figure 6 Amplicon stock-mediated cytotoxicity is not increased by additional expression of vhs and VP16 during packaging. BAC-packaged HSVlac stocks prepared in the presence or absence of VP16 and/or vhs were analyzed on confluent monolayers of NIH 3T3 cells for elicited cytotoxicity as determined by an LDH release-based assay. Two of the packaging samples that received pGRE 5 vp16 were also treated with 100 nm dexamethasone 24 h before the packaging transfection. Equivalent expression units of virus from each packaging sample were used in the transductions. Viability data were represented as normalized cell viability index. Error bars represent standard deviation. The asterisk indicates a statistically significant difference (P Ͻ 0.001) between amplicon stocks prepared with BAC plus pBS(vhs) and those made in the presence of BAC, pBS(vhs), and pGRE 5 vp16. The hash sign indicates a statistically significant difference (P Ͻ 0.001) between amplicon stocks prepared with BAC plus pBS(vhs) and those made in the presence of BAC, pBS(vhs), pGRE 5 vp16, and 100 nm dexamethasone.
vector-encoded gene product to target cells. [12] [13] [14] This phenomenon was originally described with retrovirus and adeno-associated virus vector stocks and was shown to result in an overestimation of gene transfer efficiencies. ␤-Galactosidase and alkaline phosphatase are two commonly expressed reporter proteins that have been implicated in pseudotransduction, presumably due to their relatively high enzymatic stability and sensitivity of their respective detection assays. 13 Stocks of ␤-galactosidase expressing HSVlac and GFP-expressing HSVPrPUC/ CMVegfp exhibited high levels of pseudotransduction when packaged in the absence of vhs (Figure 2 and unpublished observations). Upon addition of vhs to the previously described helper virus-free packaging protocols, 6 ,7 a 10-fold increase in expression titers and concomitant decrease in pseudotransduction were observed in vitro.
Vhs-mediated enhancement of HSV amplicon packaging was even more evident when stocks were examined in vivo. GFP-expressing cells in animals transduced with vhs(+) stocks were several hundred-fold greater in number than in animals receiving vhs(−) stocks. This could have been due to differences in virion stability, where decreased particle stability could have led to release of copackaged reporter gene product observed in the case of vhs(−) stocks. Additionally, the absence of vhs may have resulted in packaging of reporter gene product into particles that consist of only tegument and envelope. 15 Release of copackaged reporter gene product in either case could potentially activate a vigorous immune response in the CNS, resulting in much lower than expected numbers of vector-expressing cells.
Pre-loading of packaging cells with low levels of the potent HSV transcriptional activator VP16 led to a two-to five-fold additional increase in amplicon expression titers only in the presence of vhs for cosmid-and BAC-based packaging systems, respectively. This observation indicates the transactivation and structural functions of VP16 were not sufficient to increase viable viral particle production when vhs was absent, and most likely led to generation of incomplete virions containing amplicon genomes as detected by quantitative PCR. When vhs was present for viral assembly, however, VP16-mediated enhancement of genome replication led to higher numbers of viable particles formed. Quantitative PCR analysis of amplicon stocks produced in the presence of VP16 and vhs showed that viral genomes were increased only twofold while expression titers were increased five-fold over stocks produced in the presence of vhs only ( Figure 5 ). This result suggests that a portion of the effect related to VP16-mediated enhancement of genome replication while the additional two-fold enhancement in expression titers may be attributed to the structural role of VP16. The effect of VP16 on expression titers was not specific to amplicons possessing the immediate-early 4/5 promoter of HSV, as amplicons with other promoters were packaged to similar titers in the presence of VP16 and vhs (Bowers et al, unpublished observations).
VP16 is a strong transactivator protein and structural component of the HSV virion.
16 VP16-mediated transcriptional activation occurs via interaction of VP16 and two cellular factors, Oct-1 [17] [18] [19] and HCF, 20, 21 and subsequent binding of the complex to TAATGARAT elements found within HSV IE promoter regions. 22 This interaction results in robust up-regulation of IE gene expression. Neuronal splice-variants of the related Oct-2 transcription factor have been shown to block IE gene activation via binding to TAATGARAT elements, 23 suggesting that cellular transcription factors may also play a role in limiting HSV lytic growth.
The levels of VP16 appear to be important in determining its effect on expression titers. Low, basal levels of VP16 (via uninduced pGRE 5 vp16) present in the packaging cell before introduction of the packaging components induced the largest effect on amplicon expression titers. Conversely, higher expression of VP16 (via dexamethasone-induced pGRE 5 vp16) did not enhance virus production to the same degree and may have, in fact, abrogated the process. The presence of glucocorticoids in the serum components of growth medium is the most likely reason for this low-level VP16 expression, as charcoal-stripped sera significantly reduces basal expression from this construct (Bowers et al, unpublished observation). Perhaps only a low level or short burst of VP16 is required to initiate IE gene transcription, but excessive VP16 leads to disruption of the temporal progression through the HSV lytic cycle, possibly via inhibition of vhs activity. Moreover, evidence has arisen to suggest vhs activity is down-regulated by interaction with newly synthesized VP16 during the HSV lytic cycle, thereby allowing for accumulation of viral mRNAs after host transcripts have been degraded. [24] [25] [26] Therefore, a delicate regulatory protein balance may be required to attain optimal infectious particle propagation. Additionally, the 100 nm dexamethasone treatment used to induce VP16 expression may have a deleterious effect on cellular gene activity and/or interfere with replication of the OriS-containing amplicon genome in packaging cells. High levels of dexamethasone have been shown previously to repress HSV-1 OriS-dependent replication by an unknown mechanism. 27 Inhibition of OriS-dependent replication does not appear to be responsible for our results, however, since quantitative PCR analysis of amplicon stocks produced in the presence and absence of dexamethasone indicated no change in genome content as a function of drug concentration ( Figure 5 and data not shown). It is interesting to note that amplicon stocks were prepared in the presence of hexamethylene bisacetamide (HMBA). HMBA has been shown to compensate for the absence of VP16, thus leading to the transactivation of immediate-early gene promoters. 28 In the absence of HMBA pre-loading a packaging cell with VP16 could impart an even more dramatic effect on titers.
Ectopic expression of vhs and VP16 did not lead to amplicon stocks that exhibited higher cytotoxicity than helper virus-free stocks prepared in the traditional manner when examined by an LDH-release assay. Stocks prepared by the various methods were equilibrated to identical expression titers before exposure to cells. The heightened cytotoxicity in stocks produced in the absence of vhs and/or VP16 may reflect that larger volumes of these stocks were required to obtain similar expression titers as the vhs/VP16-containing samples or the levels of defective particles in the former may be significantly higher. Contaminating cellular proteins that copurify with the amplicon particles are most likely higher in concentration in the traditional stocks, and probably impart the higher toxicity profiles observed.
We recognize that further improvements in HSV amplicon production, purification, and assurances of vector safety are required before this gene delivery system can be utilized in the clinic. However, the modifications described here represent a major step forward toward realization of this goal.
Materials and methods
Cell culture Baby hamster kidney (BHK) cells were maintained as described before. 29 The NIH-3T3 mouse fibroblast cell line was originally obtained from American Type Culture Collection (Rockville, MD, USA) and maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin, and streptomycin.
Plasmid construction
The HSVPrPUC/CMVegfp amplicon plasmid was constructed by cloning the 0.8-kb cytomegalovirus (CMV) immediate-early promoter and 0.7-kb enhanced green fluorescent protein cDNA (Clontech, Palo Alto, CA, USA) into the BamHI restriction enzyme site of the pHSVPrPUC amplicon vector. 30 A 3.5 kb HpaI/HindIII fragment encompassing the UL41 (vhs) open reading Gene Therapy frame and its 5Ј and 3Ј transcriptional regulatory elements was removed from cos56 31 and cloned into pBSKSII (Stratagene, La Jolla, CA, USA) to create pBSKS(vhs). For construction of pGRE 5 vp16 the VP16 coding sequence was amplified by PCR from pBAC-V2 using gene-specific oligonucleotides that possess EcoRI (5Ј-CGGAATTCCGCAGGTTTTGTAATGTATGTG CTCGT-3Ј) and HindIII (5Ј-CTCCGAAGCTTAAGCC CGATATCGTCTTTCCCGTATCA-3Ј) restriction enzyme sequences that facilitates cloning into the pGRE 5 -2 vector.
32
Helper virus-free amplicon packaging On the day before transfection, 2 × 10 6 BHK cells were seeded on a 60-mm culture dish and incubated overnight at 37°C. For cosmid-based packaging: the day of transfection, 250 l Opti-MEM (Gibco-BRL, Bethesda, MD, USA), 0.4 g of each of the five cosmid DNAs (kindly provided by Dr A Geller, Children's Hospital, Boston, MA, USA) and 0.5 g amplicon vector DNA with or without varying amounts of pBSKS(vhs) plasmid DNA were combined in a sterile polypropylene tube. 6 For BAC-based packaging: 250 l Opti-MEM, 3.5 g of pBAC-V2 DNA (kindly provided by Dr C Strathdee, JP Robarts Institute, London, ON, Canada) and 0.5 g amplicon vector DNA with or without varying amounts of pBSKS(vhs) plasmid DNA were combined in a sterile polypropylene tube. 7 The protocol for both cosmid-and BAC-based packaging was identical from the following step forward. Ten microliters of Lipofectamine Plus Reagent (Gibco-BRL) were added over a 30-s period to the DNA mix and allowed to incubate at RT for 20 min. In a separate tube, 15 l Lipofectamine (Gibco-BRL) were mixed with 250 l Opti-MEM. Following the 20-min incubation, the contents of the two tubes were combined over a 1-min period, and incubated for an additional 20 min at RT. During the second incubation, the medium in the seeded 60-mm dish was removed and replaced with 2 ml Opti-MEM. The transfection mix was added to the flask and allowed to incubate at 37°C for 5 h. The transfection mix was then diluted with an equal volume of DMEM plus 20% FBS, 2% penicillin/streptomycin, and 2 mm hexamethylene bis-acetamide (HMBA), and incubated overnight at 34°C. The following day, medium was removed and replaced with DMEM plus 10% FBS, 1% penicillin/streptomycin, and 2 mm HMBA. The packaging flask was incubated an additional 3 days and virus harvested and stored at −80°C until purification. Viral preparations were subsequently thawed, sonicated, and clarified by centrifugation (3000 g, 20 min). Viral samples were stored at −80°C until use. For concentrated viral stocks, viral preparations were subsequently thawed, sonicated, clarified by centrifugation, and concentrated by ultracentrifugation through a 30% sucrose cushion.
33 Viral pellets were resuspended in 100 l PBS and stored at −80°C until use. For packaging experiments examining the effect of VP16 on amplicon titers, the cells plated for packaging were first allowed to adhere to the 60-mm culture dish for 5 h and subsequently transfected with pGRE 5 vp16 using the Lipofectamine reagent as described above. Following a 5-h incubation, the transfection mix was removed, complete medium (DMEM plus 10% FBS, 1% penicillin/streptomycin) was added, and the cultures were incubated at 37°C until the packaging cotransfection step the subsequent day.
Viral titering
Amplicon titers were determined by counting the number of cells expressing enhanced green fluorescent protein (HSVPrPUC/CMVegfp amplicon) or ␤-galactosidase (HSVlac amplicon). Briefly, 10 l of concentrated amplicon stock was incubated with confluent monolayers (2 × 10 5 expressing particles) of NIH 3T3 cells plated on glass coverslips. Following a 48-h incubation, cells were either fixed with 4% paraformaldehyde for 15 min at RT and mounted in Mowiol for fluorescence microscopy (eGFP visualization), or fixed with 1% glutaraldehyde and processed for X-gal histochemistry to detect the lacZ transgene product. Fluorescent or X-gal-stained cells were enumerated, expression titer calculated, and represented as either green-forming units per ml (gfu/ml) or blue-forming units per ml (bfu/ml), respectively.
TaqMan quantitative PCR system
To isolate total DNA for quantitation of amplicon genomes in packaged stocks, virions were lysed in 100-mm potassium phosphate pH 7.8 and 0.2% Triton X-100. Two micrograms of genomic carrier DNA was added to each sample. An equal volume of 2 × digestion buffer (0.2 m NaCl, 20 mm Tris-Cl pH 8, 50 mm EDTA, 0.5% SDS, 0.2 mg/ml proteinase K) was added to the lysate and the sample was incubated at 56°C for 4 h. Samples were processed further by one phenol:chloroform, one chloroform extraction, and a final ethanol precipitation. Total DNA was quantitated and 50 ng of DNA was analyzed in a PE7700 quantitative PCR reaction using a designed lacZspecific primer/probe combination multiplexed with an 18S rRNA-specific primer/probe set. The lacZ probe sequence was 5Ј-6FAM-ACCCCGTACGTCTTCCCG AGCG-TAMRA-3Ј; the lacZ sense primer sequence was 5Ј-GGGATCTGCCATTGTCAGACAT-3Ј; and the lacZ antisense primer sequence was 5Ј-TGGTGTGGGCCA-TAATTCAA-3Ј. The 18S rRNA probe sequence was 5Ј-JOE-TGCTGGCACCAGACTTGCCCTC-TAMRA-3Ј; the 18S sense primer sequence was 5Ј-CGGCTACCA-CATCCAAGGAA-3Ј; and the 18S antisense primer sequence was 5Ј-GCTGGAATTACCGCGGCT-3Ј.
Each 25-l PCR sample contained 2.5 l (50 ng) of purified DNA, 900 nm of each primer, 50 nm of each probe, and 12.5 l of 2X Perkin-Elmer Master Mix. Following a 2-min 50°C incubation and 2-min 95°C denaturation step, the samples were subjected to 40 cycles of 95°C for 15 s and 60°C for 1 min. Fluorescent intensity of each sample was detected automatically during the cycles by the Perkin-Elmer Applied Biosystem Sequence Detector 7700 machine. Each PCR run included the following: no-template control samples, positive control samples consisting of either amplicon DNA (for lacZ) or cellular genomic DNA (for 18S rRNA), and standard curve dilution series (for lacZ and 18S). Following the PCR run, 'real-time' data were analyzed using Perkin-Elmer Sequence Detector Software version 1.6.3 and the standard curves. Precise quantities of starting template were determined for each titering sample and results were expressed as numbers of vector genomes per ml of original viral stock.
Western blot analysis BHK cell monolayers (2 × 10 6 cells) transfected with varying packaging components were lysed with RIPA buffer (150 mm NaCl, 1% NP-40, 0.5% DOC, 0.5% SDS, and 50 mm Tris-Cl, pH 8). Equal amounts of protein were electrophoretically separated on a 10% SDS-PAGE gel and transferred to a PVDF membrane. The resultant blot was incubated with an anti-VP16 monoclonal antibody (Chemicon, Temecula, CA, USA), and specific VP16 immunoreactive band visualized using an alkaline phosphatase-based chemiluminescent detection kit (ECL).
Cytotoxicity assays
The effect of BAC-packaged HSVlac stocks prepared in the presence or absence of VP16 and/or vhs on cell viability was determined using a lactate dehydrogenase (LDH) release-based assay (Promega, Madison, WI, USA). Equivalent expression units of virus from each packaging sample were used to transduce 5 × 10 3 NIH 3T3 cells in 96-well flat-bottomed culture dishes. Quantitation of LDH release was performed according to the manufacturer's instructions. Viability data were represented as normalized cell viability index.
Stereotactic injections
Mice were anesthetized with avertin at a dose of 0.6 ml per 25 g body weight. After positioning in an ASI murine stereotactic apparatus, the skull was exposed via a midline incision, and burr holes were drilled over the following coordinates (bregma, +0.5 mm; lateral −2.0 mm; and deep, −3.0 mm) to target infections to the striatum. A 33 GA steel needle was gradually advanced to the desired depth, and 3 l (equivalent in vitro titer) HSVPrPUC/CMVegfp virus was infused via a microprocessor-controlled pump over 10 min (UltraMicroPump; World Precision Instruments, Sarasota Springs, FL, USA). The injector unit was mounted on a precision small animal stereotactic frame (ASI Instruments, Warren, MI, USA) micromanipulator at a 90°angle using a mount for the injector. Viral injections were performed at a constant rate of 300 nl/min. The needle was removed slowly over an additional 10-min period.
Tissue preparation and GFP visualization Infected mice were anesthetized 4 days later, a catheter was placed into the left ventricle, and intracardiac perfusion was initiated with 10 ml of heparinized saline (5000 U/l saline) followed by 60 ml of chilled 4% PFA. Brains were extracted and postfixed for 1-2 h in 4% PFA at 4°C. Subsequently, brains were cryoprotected in a series of sucrose solutions with a final solution consisting of a 30% sucrose concentration (w/v) in PBS. Forty micron serial sections were cut on a sliding microtome (Micron/Zeiss, Thornwood, NY, USA) and stored in a cryoprotective solution (30% sucrose (w/v), 30% ethylene glycol in 0.1 m phosphate buffer (pH 7.2)) at −20°C until processed for GFP visualization. Sections were placed into Costar net wells (VWR, Springfield, NJ, USA) and incubated for 2 h in 0.1 m Tris buffered saline (TBS) (pH 7.6). Upon removal of cryoprotectant, two additional 10-min washes in 0.1 m TBS with 0.25% Triton X-100 (Sigma, St Louis, MO, USA) were performed. Sections were mounted with a fine paint brush on to subbed slides, allowed to air dry, and mounted with an aqueous mounting media, Mowiol. GFP-positive cells were visualized with a fluorescent microscope (Axioskop, Zeiss) utilizing a FITC cube (Chroma Filters, Brattleboro, VT, USA). All images used for morphological analyses were digitally acquired with a three-chip color CCD camera at 200 × magnification (DXC-9000; Sony, Montvale, NJ, USA).
Morphological analyses
Cell counts were performed on digital images acquired within 24 h of mounting. At the time of tissue processing coronal slices were stored serially in three separate compartments. All compartments were processed for cell counting and GFP(+) cell numbers reflect cell counts throughout the entire injection site. All spatial measurements were acquired using an image analysis program (Image-Pro Plus, Silver Spring, MD, USA) at a final magnification of 200 ×. Every section was analyzed using identical parameters in three different planes of focus throughout the section to prevent repeated scoring of GFP(+) cells. Each field was analyzed by a computer macro to count cells based on the following criteria: object area, image intensity (fluorescent signal) and plane of focus. Only cells in which the cell body was unequivocally GFP(+) and nucleus clearly defined were counted. Every section that contained a GFP(+) cell was counted. In addition, a watershed separation technique was applied to every plane of focus in each field to delineate overlapping cell bodies. The watershed method is an algorithm that is designed to erode objects until they disappear, then dilates them again such that they do not touch.
Statistical analyses
Statistical analyses were carried out using one-way analysis of variance (ANOVA) with plasmid construct as the between-group variable. Two-way repeated measure analyses of variance (RMANOVA) were carried out using plasmid construct as the between-group variable and time interval as a within-group variable.
